Altimmune Q2 net loss $20.1M ($0.42/share); cash $184.8M; pemvidutide Phase 1b data mid-Sept

Altimmune, Inc.

2022-Q2 EPS reported -$0.90 revenue$40,000

Net loss of $20.1M ($0.42 per share) for Q2 2022 vs $24.8M ($0.60) in Q2 2021, which included $8.1M impairment.
Cash, equivalents, and short-term investments $184.8M at June 30, 2022.
R&D expenses $16.0M in Q2 2022, up from $13.3M, primarily on pemvidutide development.
Pemvidutide Phase 1b obesity/NAFLD topline data expected mid-September 2022; Phase 2 MOMENTUM interim analysis (160 subjects) expected Q1 2023.
HepTcell Phase 2 chronic hepatitis B trial enrollment ongoing; data expected H2 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.